United Therapeutics (NASDAQ:UTHR) EVP Sells $4,802,600.00 in Stock

Key Points

• Paul Mahon, Executive Vice President of United Therapeutics, sold 11,000 shares for a total of $4,802,600, reducing his stake by 23.02% and leaving him with approximately 36,781 shares valued at $16 million.
• United Therapeutics reported earnings per share (EPS) of $6.41 for the most recent quarter, missing analyst expectations of $6.80, but still showing a revenue increase of 11.7% year-over-year.
• Analysts have raised their price targets for United Therapeutics, with UBS Group setting a new target at $580, highlighting a consensus rating of "Moderate Buy" and a target price of $449.57.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $436.60, for a total transaction of $4,802,600.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $16,058,584.60. The trade was a 23.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded up $5.26 during midday trading on Thursday, hitting $443.44. The company had a trading volume of 969,615 shares, compared to its average volume of 593,636. The business's 50 day simple moving average is $350.60 and its two-hundred day simple moving average is $317.22. The stock has a market cap of $20.00 billion, a PE ratio of 17.31, a P/E/G ratio of 6.39 and a beta of 0.66. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $444.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the previous year, the business posted $5.85 EPS. The company's revenue was up 11.7% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new position in United Therapeutics during the 1st quarter worth approximately $313,000. Allianz Asset Management GmbH boosted its stake in United Therapeutics by 96.9% during the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after acquiring an additional 33,254 shares during the last quarter. LPL Financial LLC grew its position in shares of United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after purchasing an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at approximately $227,000. Institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on UTHR. UBS Group lifted their price target on shares of United Therapeutics from $560.00 to $580.00 and gave the stock a "buy" rating in a research note on Monday. HC Wainwright lifted their price target on United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a report on Friday, September 5th. Bank of America lifted their price target on United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Jefferies Financial Group lifted their price target on United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Finally, Wells Fargo & Company lifted their price target on United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a report on Wednesday, September 3rd. Ten analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $449.57.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.